Fig. 4

ARNP efficiently accumulates in primary tumors and bone metastases. (A) In vivo DiD fluorescence images showing the primary tumor and bone metastasis of different intravenous treatments at different time points. (B) Ex vivo images showing the biodistribution of NP, RNP, mRNP and ARNP in major organs (left to right: heart, liver, spleen, lung, kidney) at 24 h post-injection. (C) Ex vivo fluorescence images of primary tumors at 24 h postinjection. (D) Ex vivo fluorescence images of bone metastasis at 24 h post-injection. (E) Semiquantitative analysis of major organs and tumors based on ex vivo fluorescence images. (F) Confocal images showing the distribution of NP, RNP, mRNP and ARNP in primary tumors and bone metastases (blue represents DAPI, red represents DiD). All data are presented as the mean ± SD (n = 3). *p < 0.05, **p < 0.01